162 related articles for article (PubMed ID: 9399607)
21. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
23. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
Guo JH
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
Kelsen DP; Alcock N; Young CW
Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
[TBL] [Abstract][Full Text] [Related]
25. A short outpatient hydration schedule for cisplatin administration.
Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
Hohnloser JH; Schierl R; Hasford B; Emmerich B
Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
29. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease.
Hasei M; Uchiyama A; Nishimura M; Mashimo T; Fujino Y
Acta Anaesthesiol Scand; 2008 Aug; 52(7):991-6. PubMed ID: 18477069
[TBL] [Abstract][Full Text] [Related]
30. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
31. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
[TBL] [Abstract][Full Text] [Related]
32. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
33. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV; Iasonos A; Herr H; Donat SM
J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
[TBL] [Abstract][Full Text] [Related]
34. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
35. Mild and moderate renal dysfunction: impact on short-term outcome.
Simon C; Luciani R; Capuano F; Miceli A; Roscitano A; Tonelli E; Sinatra R
Eur J Cardiothorac Surg; 2007 Aug; 32(2):286-90. PubMed ID: 17555972
[TBL] [Abstract][Full Text] [Related]
36. The potential nephrotoxic effects of intensity modulated radiotherapy delivered to the para-aortic area of women with gynecologic malignancies: preliminary results.
Varlotto JM; Gerszten K; Heron DE; Comerci J; Gautam S; Selvaraj R; Lalonde R; Chura JC
Am J Clin Oncol; 2006 Jun; 29(3):281-9. PubMed ID: 16755182
[TBL] [Abstract][Full Text] [Related]
37. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
38. [Effect of arterial pressure and age on renal function, The "Care for the Kidney" study].
Olivares J; Guillén F; Sánchez JJ; Morales-Olivas FJ
Nefrologia; 2003; 23(2):137-44. PubMed ID: 12778878
[TBL] [Abstract][Full Text] [Related]
39. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
